GJMic.070103

Review

Gut Microbiota in Hematologic Malignancies: Current Status and Innovative Framework Development

Zhi Guo1,*

1Department of Hematology, Affiliated Nanshan Hospital of Shenzhen University, Shenzhen 518052, China.

*, Correspondence
Professor Zhi Guo, Ph.D., Department of Hematology, Affiliated Nanshan Hospital of Shenzhen University, Shenzhen 518052, China. Email: guozhi77@126.com.
Received: May 31, 2026; Accepted: July 20, 2026; Published online: November 12, 2026.
Cite this paper: Zhi Guo. Gut microbiota in hematologic malignancies: current status and innovative framework development. Global Journal of Microbiology, 2026;7(1):9-15. http://naturescholars.com/gjmic.070103. https://doi.org/10.46633/gjmic.070103.
Copyright© 2026 by Scholars Publishing, LLC.

Abstract

Patients with hematologic malignancies often suffer from gut microbiota dysbiosis after chemotherapy, radiotherapy, or hematopoietic stem cell transplantation, which leads to severe complications such as mucositis, graft-versus-host disease (GVHD), multidrug-resistant bacterial infections, and persistent immune dysfunction. These adverse events greatly compromise treatment tolerance, long-term survival, and patients’ quality of life. Microecological interventions, including fecal microbiota transplantation (FMT) and probiotic therapies, have exhibited great potential for preventing and managing treatment-related complications and enhancing anti-tumor effects. Nevertheless, a standardized research system has not yet been established in this field, and multiple technical bottlenecks remain unresolved. This article elaborates on five major challenges: limitations in microbiota detection and prognostic modeling, inadequate intervention strategies for gastrointestinal complications, translational obstacles of FMT in GVHD treatment, difficulties in the microecological control of multidrug-resistant infections, and unclear synergistic mechanisms between gut microbiota and immunotherapy. An innovative research framework covering spatiotemporal multi-omics analysis, AI-driven predictive modeling, stratified precision intervention, and mechanistic exploration is accordingly proposed. This framework helps interpret the regulatory rules of the microbiota-immune-metabolic axis, promotes the standardization and individualization of microecological therapies, and facilitates the advancement of precision medicine for hematologic malignancies.

Keywords

Gut microbiota; hematologic malignancies; fecal microbiota transplantation; graft-versus-host disease; precision intervention.